Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors

Abstract

The present invention provides methods for inhibiting Fyn kinase, using 5-3-pyridin-2-amine, 6-3-imidazo[1,2-a] pyrazine, 6-3-imidazo[1,2-b] pyridazine, N-(5-imidazo [2,1-b][1,3,4] thiadiazol-2-yl)-amine, 4-3-1H-pyrazolo[3,4-b] pyridine, and N-(3-imidazo [1,2-b] pyridazin-6-yl) amine compounds and methods of treatment, prevention, inhibition or amelioration of diseases and conditions associated with Fyn kinase using such compounds.

1 . A compound of formula (I): 
       
         
           
           
               
               
           
         
         wherein:
 R1 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate, and 
 R2 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate. 
 
       
     
     
         2 . A method of treating, or slowing progression of, a disease associated with Fyn kinase, said method comprising administering a therapeutically effective amount of at least one compound according to  claim 1 , or pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof. 
       
         
           
           
               
               
           
         
       
     
     
         3 . The compound of  claim 1 , wherein the compound is selected from the group consisting of 3-[2-amino-5-(3,4-dimethoxyphenyl-3 pyridyl]phenol, 3-[6-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]-N-(2-hydroxyethyl)benzamide, 5-(3-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[2-amino-5-(4-methylsulfonylphenyl)-3-pyridyl]-2-methoxy-phenol, 4-[2-amino-5-(p-tolyl)-3-pyridyl]-2-methoxy-phenol, 4-[2-amino-5-(3-chlorophenyl)-3-pyridyl]-2-methoxy-phenol, 4-[2-amino-5-(3-fluorophenyl)-3-pyridyl]-2-methoxy-phenol, 4-(2-amino-5-phenyl-3-pyridyl)-2-methoxy-phenol, 4-[6-amino-5-(4-hydroxy-3-methoxy-phenyl)-3-pyridyl]-2,6-dimethyl-phenol, 4-[2-amino-5-(4-fluorophenyl)-3-pyridyl]-2-methoxy-phenol, 4-[2-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]-2-methoxy-phenol, 4-[6-amino-5-[4-(methoxymethoxy)phenyl]-3-pyridyl] benzamide, 3-[6-amino-5-[4-(methoxymethoxy)phenyl]-3-pyridyl]phenyl]methanol, 3-[6-amino-5-[4-(methoxymethoxy)phenyl]-3-pyridyl]benzamide, N-[3-[6-amino-5-[4-(methoxymethoxy)phenyl]-3-pyridyl]phenyl]acetamide, 4-[6-amino-5-[4-(hydroxymethyl)phenyl]-3-pyridyl]-2,6-dimethyl-phenol, 3-[4-(methoxymethoxy)phenyl]-5-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 3-[2-amino-5-(4-morpholinophenyl)-3-pyridyl]phenol, N-[3-[6-amino-5-(4-hydroxyphenyl)-3-pyridyl]phenyl]acetamide, 4-[2-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]phenol, 4-[2-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]phenol, 3-[2-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]phenol, 4-[2-amino-5-(4-methylsulfonylphenyl)-3-pyridyl]phenol, 3-(3-aminophenyl)-5-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[2-amino-5-(3-methoxyphenyl)-3-pyridyl]phenol, 4-[6-amino-5-(4-pyridyl)-3-pyridyl]-2,6-dimethyl-phenol, 5-[6-[3-(dimethylamino)propoxy]-3-pyridyl]-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 5-(3-fluorophenyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]-2,6-dimethyl-phenol, N-[3-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]phenyl]methanesulfonamide, 5-phenyl-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 3-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]-N-(2-hydroxyethyl)benzamide, 5-(4-aminophenyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]phenol, 5-(4-fluorophenyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]-N-cyclopropyl-benzamide, 5-(benzothiophen-2-yl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 3-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]phenol, 5-(6-methoxy-3-pyridyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 5-[3-(dimethylamino)phenyl]-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, [3-[6-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]phenyl]-(4-methylpiperazin-1-yl)methanone, 4-[6-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]-2-methoxy-phenol, 3-[3-(dimethylamino)phenyl]-5-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[6-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]-2,6-dimethyl-phenol, 3-[3-(dimethylamino)phenyl]-5-(3-pyridyl)pyridin-2-amine, [3-[6-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]phenyl]methanol, 3-[3-(dimethylamino)phenyl]-5-[6-[3-(dimethylamino)propoxy]-3-pyridyl]pyridin-2-amine, 3-[6-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]benzamide, 5-(3,4-dimethoxyphenyl)-3-[3-(dimethylamino)phenyl]pyridin-2-amine, 4-[2-amino-5-(3-chloro-4-fluoro-phenyl)-3-pyridyl]-2-methoxy-phenol, 5-(4-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[2-amino-5-(4-methoxyphenyl)-3-pyridyl]-2-methoxy-phenol, 5-(3-furyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 5-(2-phenoxyphenyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]benzamide, 4-[2-amino-5-(3-methoxyphenyl)-3-pyridyl]-2-methoxy-phenol, [4-[2-amino-5-(3,4-dimethoxyphenyl)-3-pyridyl]phenyl]methanol, 5-[4-(4-methylpiperazin-1-yl)phenyl]-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 3-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]benzamide, 1-[5-[6-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]-2-thienyl]ethanone, 5-(4-methylsulfonylphenyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[6-amino-5-(4-hydroxyphenyl)-3-pyridyl]benzamide, 4-[2-amino-5-[4-(4-methylpiperazin-1-yl)phenyl]-3-pyridyl]phenol, 4-[2-amino-5-[4-(4-methylpiperazin-1-yl)phenyl]-3-pyridyl]-2-methoxy-phenol, 4-[6-amino-5-(4-hydroxy-3-methoxy-phenyl)-3-pyridyl]benzamide, 4-[2-amino-5-(4-piperazin-1-ylphenyl)-3-pyridyl]-2-methoxy-phenol, 3,5-bis(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[2-amino-5-[4-(4-isopropylpiperazin-1-yl)phenyl]-3-pyridyl]-2-methoxy-phenol, 4-[2-amino-5-(4-morpholinophenyl)-3-pyridyl]-2-methoxy-phenol, and 5-[6-amino-5-[4-(4-methylpiperazin-1-yl)phenyl]-3-pyridyl]-2-methoxy-phenol. 
     
     
         4 . A compound of formula (II): 
       
         
           
           
               
               
           
         
         wherein:
 R1 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate, and 
 R2 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate. 
 
       
     
     
         5 . A method of treating, or slowing progression of, a disease associated with Fyn kinase, said method comprising administering a therapeutically effective amount of at least one compound according to  claim 4 , or pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof. 
       
         
           
           
               
               
           
         
       
     
     
         6 . The compound of  claim 4 , wherein the compound is selected from the group consisting of N-(2-hydroxyethyl)-4-[3-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 3-[3-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]-N,N-dimethyl-benzamide, 4-[6-[4-(4-isopropylpiperazin-1-yl)phenyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[6-(1-benzylpyrazol-4-yl)imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[3-(2-thienyl)imidazo[1,2-a] pyrazin-6-yl]phenol, 3,6-bis(2-thienyl)imidazo[1,2-a]pyrazine, N-(2-hydroxyethyl)-3-[3-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, N-cyclopropyl-4-[3-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[6-[4-(4-methylpiperazin-1-yl)phenyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[6-(6-amino-3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 5-[3-(2-thienyl)imidazo[1,2-a]pyrazin-6-yl]pyridin-2-amine, 4-[3-(3-acetylphenyl)imidazo[1,2-a]pyrazin-6-yl]-N-(2-dimethylaminoethyl)benzamide, N-(2-dimethylaminoethyl)-4-[3-(2-thienyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[3-(3,5-dimethoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]-N-[3-(dimethylamino)propyl]benzamide, N-(2-dimethylaminoethyl)-4-[3-(4-pyridyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[6-[2-(dimethylamino)phenyl]imidazo[1,2-a]pyrazin-3-yl]-2-methoxy-phenol, N-(2-hydroxyethyl)-3-[3-(4-hydroxy-3-methoxy-phenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 2-methoxy-4-[6-(3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[6-(2-chlorophenyl)imidazo[1,2-a]pyrazin-3-yl]-2-methoxy-phenol, 4-[6-(3-ethoxyphenyl)imidazo[1,2-a]pyrazin-3-yl]-2-methoxy-phenol, N-(2-dimethylaminoethyl)-4-[3-(4-hydroxy-3-methoxy-phenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[6-(6-amino-3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]-2-methoxy-phenol, 2-methoxy-4-[6-[6-(4-methylpiperazin-1-yl)-3-pyridyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 2-methoxy-4-[6-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyrazin-3-yl]phenol, N-[3-[3-(3,4,5-trimethoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]phenyl]methanesulfonamide, N-[3-(dimethylamino)propyl]-4-[3-(4-hydroxy-3-methoxy-phenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 2-methoxy-4-[6-[6-(2-morpholinoethylamino)-3-pyridyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 6-(1-methylpyrazol-4-yl)-3-(3-thienyl)imidazo[1,2-a]pyrazine, 6-phenyl-3-(3-thienyl)imidazo[1,2-a]pyrazine, [4-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]phenyl]methanol, 4-[3-(4-methoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]phenol, 6-(3-pyridyl)-3-(3-thienyl)imidazo[1,2-a]pyrazine, 3-(4-pyridyl)-6-(2-thienyl)imidazo[1,2-a]pyrazine, 4-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]phenol, 6-(2-thienyl)-3-(3-thienyl)imidazo[1,2-a]pyrazine, N-[3-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]phenyl]acetamide, N-[3-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]phenyl]methanesulfonamide, 6-(2-furyl)-3-(3-thienyl)imidazo[1,2-a]pyrazine, 3-(6-phenylimidazo[1,2-a]pyrazin-3-yl)phenol, 3-[3-(3-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[6-(3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]phenol, [4-[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]phenyl]methanol, 4-[6-(4-chlorophenyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 3-[6-(2-thienyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 6-(1-methylpyrazol-4-yl)-3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazine, 3-[6-(2-furyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[6-(6-methoxy-3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 3-[6-[4-(hydroxymethyl)phenyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 3-[6-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[6-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyrazin-3-yl]phenol, 6-[6-(4-methylpiperazin-1-yl)-3-pyridyl]-3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazine, N-(2-hydroxyethyl)-3-[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, N-(2-dimethylaminoethyl)-4-[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, N-(2-hydroxyethyl)-4-[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[3-(3-chlorophenyl)imidazo[1,2-a]pyrazin-6-yl]-N-[3-(dimethylamino)propyl]benzamide, 5-[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]pyridin-2-amine, N-[3-(dimethylamino)propyl]-4-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 3-(4-methoxyphenyl)-6-[4-(4-methylpiperazin-1-yl)phenyl]imidazo[1,2-a]pyrazine, N-(2-hydroxyethyl)-3-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 6-[6-(4-methylpiperazin-1-yl)-3-pyridyl]-3-(3-thienyl)imidazo[1,2-a]pyrazine, 5-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]pyridin-2-amine, 3,6-bis(3-thienyl)imidazo[1,2-a]pyrazine, N-(2-dimethylaminoethyl)-4-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 3-(1-methylpyrazol-4-yl)-6-(2-phenoxyphenyl)imidazo[1,2-a]pyrazine, 3-[6-[6-(4-methylpiperazin-1-yl)-3-pyridyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 3-[[5-[3-(1,3-benzodioxol-5-yl)imidazo[1,2-a]pyrazin-6-yl]-2-pyridyl]oxy]-N,N-dimethyl-propan-1-amine, 3-[6-(3-ethoxyphenyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 3-(1,3-benzodioxol-5-yl)-6-[4-(4-methylpiperazin-1-yl)phenyl]imidazo[1,2-a]pyrazine, 3-[6-(3-thienyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 3-[6-[4-(4-methylpiperazin-1-yl)phenyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[3-(4-chlorophenyl)imidazo[1,2-a]pyrazin-6-yl]-N-[3-(dimethylamino)propyl]benzamide, 4-[3-(1,3-benzodioxol-5-yl)imidazo[1,2-a]pyrazin-6-yl]-N-(2-dimethylaminoethyl)benzamide, 3-[6-(6-amino-3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]phenol, N-(2-dimethylaminoethyl)-4-[3-(3-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[3-(4-chlorophenyl)imidazo[1,2-a]pyrazin-6-yl]-N-(2-dimethylaminoethyl)benzamide, 3-[6-[6-(2-morpholinoethylamino)-3-pyridyl]imidazo[1,2-a]pyrazin-3-yl]phenol, N-[3-(dimethylamino)propyl]-4-[3-(3-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, N-(2-hydroxyethyl)-4-[3-(3-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[3-(1,3-benzodioxol-5-yl)imidazo[1,2-a]pyrazin-6-yl]-N-[3-(dimethylamino)propyl]benzamide, 6-[6-(4-methylpiperazin-1-yl)-3-pyridyl]-3-phenyl-imidazo[1,2-a]pyrazine, 3-[6-[4-(4-isopropylpiperazin-1-yl)phenyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 5-[3-(1,3-benzodioxol-5-yl)imidazo[1,2-a]pyrazin-6-yl]pyridin-2-amine, 4-[6-[6-[3-(dimethylamino)propoxy]-3-pyridyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[6-[6-(2-morpholinoethylamino)-3-pyridyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[6-[6-(4-methylpiperazin-1-yl)-3-pyridyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 3-[2-(cyclohexylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-N,N-dimethyl-benzamide, N-[2-(dimethylamino)ethyl]-4-[3-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, N-[2-(dimethylamino)ethyl]-4-[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, N-[3-(dimethylamino)propyl]-4-[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, N-[2-(dimethylamino)ethyl]-4-[3-(4-hydroxy-3-methoxy-phenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, and 4-[6-[[(1S)-1-(hydroxymethyl)-2-methyl-propyl]amino]imidazo[1,2-b]pyridazin-3-yl]-2-methoxy-phenol. 
     
     
         7 - 23 . (canceled) 
     
     
         24 . A method of ameliorating or preventing a disorder associated with Fyn kinase, said method comprising administering a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, wherein the compound is selected from the group consisting of compounds comprising an SFK40 pharmacore or an SFK43 pharamcore. 
     
     
         25 . The method of  claim 24 , wherein the disease associated with Fyn kinase is selected from the group of disorders consisting of Type I diabetes, Type II diabetes, pre-diabetes, breast cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric cancer, liver cancer, bowel cancer, melanoma, Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease. 
     
     
         26 - 28 . (canceled) 
     
     
         29 . A method for ameliorating and improving physiologic functions associated with Fyn kinase, said method comprising administering an effective amount of at least one compound, or pharmaceutically acceptable salt or solvate of the compound to a subject in need thereof, wherein the compound is selected from the group consisting of compounds comprising an SFK40 pharmacore or an SFK43 pharamcore.